Health Care [ 8/12 ] | Biotechnology [ 29/73 ]
NASDAQ | Common Stock
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease.
The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic and genetic insights to clinicians prescribing to help improve chronic care management.
It also provides CardioInnovate360, a research-use-only solution to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases; and HeartRisk, a SaaS cardiovascular disease risk intelligence platform.
It serves telemedicine providers; provider organizations, including concierge practices, longevity clinics, and risk-bearing provider organizations; and employer organizations.
Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 15, 25 | -0.97 Decreased by -385.00% | -0.21 Decreased by -361.90% |
| Mar 20, 25 | -0.04 Increased by +96.24% | -0.18 Increased by +77.78% |
| Nov 27, 24 | -1.80 Decreased by -1.02 K% | -1.50 Decreased by -20.00% |
| Aug 28, 24 | -1.80 Decreased by -361.54% | -2.70 Increased by +33.33% |
| May 15, 24 | -0.20 Decreased by -122.22% | -0.09 Decreased by -122.22% |
| Feb 28, 24 | -1.06 Decreased by -254.30% | -0.14 Decreased by -687.33% |
| Nov 13, 23 | -0.16 Decreased by -900.00% | -0.28 Increased by +42.86% |
| Aug 14, 23 | -0.39 Increased by +26.42% | -0.18 Decreased by -116.67% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 940.00 Decreased by -94.10% | -1.64 M Increased by +60.73% | Decreased by -173.94 K% Decreased by -565.43% |
| Dec 31, 24 | 4.51 K Decreased by -15.03% | -1.52 M Decreased by -9.39% | Decreased by -33.67 K% Decreased by -28.73% |
| Sep 30, 24 | 6.58 K Decreased by -34.40% | -1.41 M Increased by +26.90% | Decreased by -21.47 K% Decreased by -11.43% |
| Jun 30, 24 | 7.87 K Increased by +356.23% | -1.29 M Increased by +67.98% | Decreased by -16.37 K% Increased by +92.98% |
| Mar 31, 24 | 15.93 K Increased by +N/A% | -4.16 M Decreased by -303.06% | Decreased by -26.14 K% Decreased by N/A% |
| Dec 31, 23 | 5.31 K Increased by +458.95% | -1.39 M Increased by +41.59% | Decreased by -26.16 K% Increased by +89.55% |
| Sep 30, 23 | 10.03 K Increased by +N/A% | -1.93 M Decreased by -67.89% | Decreased by -19.27 K% Decreased by N/A% |
| Jun 30, 23 | 1.73 K Increased by +N/A% | -4.02 M Decreased by -377.79% | Decreased by -233.22 K% Decreased by N/A% |